In recent years, with the rapid development of molecular biology and immunology, tumor biotherapy has become the fourth mode of tumor treatment after surgery, radiotherapy and chemotherapy, and has been gradually accepted by the majority of medical practitioners for its safety, effectiveness and small side effects. It is now believed that postoperative treatment of solid tumor patients can be more effective if it is supplemented with specific biologic therapy programs under the principle of comprehensive treatment. Tumor biotherapy refers to the treatment method to inhibit or eliminate tumor growth by regulating the biological response of the body through the action of muscle defense mechanism or biological agents. It includes tumor gene therapy and tumor immunotherapy. Biological therapy used to be mainly performed in some tumors with strong immunogenicity: e.g. melanoma. Kidney cancer. Malignant glioma, etc. With the progress of biologic therapy research, it has been expanded to other tumors, such as breast cancer. Lung cancer. Bowel cancer. Prostate cancer. Ovarian cancer. Cervical cancer and liver cancer. In the biological treatment of tumors, the induction of myocardial anti-tumor immunity by dendritic cell delivery of tumor antigens has become a hot topic in clinical trials. As the most powerful antigen-presenting cells in vivo, dendritic cells (DCs) have shown promising applications in tumor biotherapeutic research focusing on tumor antigen recognition by T cells. Dendritic cells (DCs) express high levels of stimulatory molecules that can directly activate initial T cells in vitro and in vivo, promote the proliferation of T helper cells and cytotoxic T lymphocytes, and also promote antibody production by B cells. With the uptake of DCs. With the continuous understanding of the mechanism of antigen delivery, the DC culture method has been matured and improved to target the weak immunogenicity of tumors. MHC molecules are down-regulated or absent. The design of DC vaccines has become one of the hot spots in the field, such as the immune characteristics of antigen processing and delivery disorders. These developments have laid the theoretical and experimental foundation for opening up new avenues of biological control of tumors. In foreign countries, clinical trials of DC/tumor fusion cell vaccine for tumor treatment have been conducted in many countries, but few of them have been conducted in China. The implementation of this project will improve the level of tumor biotherapy in China and better serve cancer patients.